First Tracks Biotherapeutics (HAM:B43) Retained Earnings: €0.00 Mil (As of Dec. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HAM:B43 First Tracks Biotherapeutics Inc HAM:B43
20 GF Score
Price €37.60
! 2 Warning Signs
View Full Analysis

What is First Tracks Biotherapeutics Retained Earnings?

First Tracks Biotherapeutics HAM:B43 -2.84% 20 Retained Earnings is €0.00 Mil as of Dec. 2024. GuruFocus rates HAM:B43 with a GF Score™ of 20/100. The stock has 2 warning signs investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. First Tracks Biotherapeutics's retained earnings for the quarter that ended in Dec. 2024 was €0.00 Mil.


First Tracks Biotherapeutics  (HAM:B43) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


First Tracks Biotherapeutics Retained Earnings Historical Data

* Premium members only.

The historical data trend for First Tracks Biotherapeutics's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

First Tracks Biotherapeutics Retained Earnings Chart

First Tracks Biotherapeutics Annual Data
Trend Dec23 Dec24
Retained Earnings
0.00 0.00

First Tracks Biotherapeutics Semi-Annual Data
Dec23 Dec24
Retained Earnings 0.00 0.00
HAM:B43
20GF Score
First Tracks Biotherapeutics Inc HAM:B43
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

First Tracks Biotherapeutics Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of €0.00 Mil mean?
First Tracks Biotherapeutics (HAM:B43) has a Retained Earnings of €0.00 Mil as of Dec. 2024. Retained earnings is the amount of net income not issued to shareholders. View historical data on First Tracks Biotherapeutics and its competitors.
Is First Tracks Biotherapeutics' Retained Earnings too high?
First Tracks Biotherapeutics' current Retained Earnings is €0.00 Mil. Overall, First Tracks Biotherapeutics has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does First Tracks Biotherapeutics' Retained Earnings compare to AVLN and IMTX?
First Tracks Biotherapeutics' Retained Earnings of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Biotechnology company?
A good Retained Earnings depends on the Biotechnology industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on First Tracks Biotherapeutics and its competitors. First Tracks Biotherapeutics's current Retained Earnings is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is First Tracks Biotherapeutics stock overvalued right now?
First Tracks Biotherapeutics (HAM:B43) has a current Retained Earnings of €0.00 Mil. The current Retained Earnings is €0.00 Mil. First Tracks Biotherapeutics' overall GF Score™ is 20/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For First Tracks Biotherapeutics (HAM:B43), the current Retained Earnings is €0.00 Mil as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

First Tracks Biotherapeutics Business Description

Other Exchanges TRAX:USA
Address 10770 Wateridge Circle, Suite 210, San Diego, CA, USA, 92121
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.
20GF Score

Get the complete analysis for HAM:B43

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€37.60
Price